GC (Green Cross) said on Dec. 6 that there has been a case of complete recovery after administering COVID-19 blood treatment developed by GC.
The company said that a man in his 70s, who was confirmed to be COVID-19, was completely cured after receiving GC's blood treatment "GC5131A" at Kyungpook National University Hospital in Chilgok in September.
GC has developed a blood treatment called "GC5131A" that divides immune-natured antibodies from the plasma of COVID-19 cured patients and is conducting clinical two-phase tests on patients with high-risk groups.
The patient was not a participant in the clinical trial, but a medical team applied for approval for the use of the treatment to the Ministry of Food and Drug Safety.
He was prescribed anti-viral drugs Remdesibir and steroid drugs Dexamethasone after being tested positive for COVID-19, but medical staff reportedly tried to administer blood-stained drugs because he did not improve.
After about 20 days of treatment, he was finally tested negative on Nov. 18 and was released from quarantine.
A GC spokesman said, "We do not currently have all the data on 13 cases, but it is true that there has been a case of complete recovery among patients who administered blood treatment at Kyungpook National University Hospital in Chilgok."